TickerGraveyard
TickerGraveyard

TSOI

Delisted
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

TSOI — Post-Mortem

Therapeutic Solutions International, Inc. (TSOI), engaged in biotechnology and health solutions, announced a significant strategic shift on April 22, 2025, when its Board of Directors, with majority shareholder consent, approved a voluntary withdrawal from the OTC Markets. The move aimed to reevaluate operational strategies and streamline focus. Following the Board's decision, the company issued a formal notification to the SEC, detailing its intent to file Form 25 to remove its securities from listing, and outlined next steps to complete the delisting process. By April 24, 2025, the company had publicly confirmed these developments, marking a decisive endpoint in its market presence as it transitioned into a new phase, potentially outside the public trading spotlight.

Therapeutic Solutions International, Inc. voluntarily delisted its securities from the OTC Markets on April 22, 2025, due to strategic considerations.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Founded as a Nevada corporation, Therapeutic Solutions International, Inc. began trading on OTC Markets, primarily focusing on innovative health solutions.

Peak

CEO Timothy Dixon led the company during its most active period around 2020, when it gained attention in the biotech sector for its therapeutic approaches.

Turning Point

The decision to delist on April 22, 2025, reflected declining operational performance and strategic reevaluation amid challenging market conditions.

End

TSOI ceased trading on OTC Markets after filing the necessary documentation with the SEC, effectively concluding its public trading activities.

Impact

The company's delisting could limit access to capital and diminish shareholder liquidity, creating potential challenges for future operations.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Investors should critically assess management's actions and statements surrounding delistings, often reflective of underlying business viability.

  2. 2

    Regulatory filings provide crucial insights into a company's strategic decisions, emphasizing the need for thorough due diligence by investors.

  3. 3

    The complexities of OTC markets may prompt companies to seek delisting as a method of restructuring or realignment, highlighting the importance of understanding market dynamics.

Frequently Asked Questions

What was the primary reason for Therapeutic Solutions International, Inc.'s delisting?
The company voluntarily withdrew its class of securities from listing and registration on the OTC Markets on April 22, 2025.
When was the delisting notice filed with the SEC?
The notice was filed on April 24, 2025, following the board's decision.
What are the subsequent steps after the delisting notice?
Following the delisting notice, the company plans to file Form 25 for removal from listing and later Form 15 to terminate its registration.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: